The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3
| Autor: | A L, Voigts, A J, Felsenfeld, F, Llach |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
Adult
24 25-Dihydroxyvitamin D 3 Hydroxycholecalciferols Osteitis Fibrosa Cystica Alkaline Phosphatase Prognosis Bone and Bones Phosphates Rats Radiography Calcitriol Parathyroid Hormone Renal Dialysis Osteomalacia Dihydroxycholecalciferols Hypercalcemia Animals Humans Kidney Failure Chronic Drug Therapy Combination Magnesium Child Chelating Agents Densitometry |
| Zdroj: | Archives of internal medicine. 143(6) |
| ISSN: | 0003-9926 |
| Popis: | The available data with regard to the use of calcitriol, 1 alpha-hydroxyvitamin D3 (1 alpha-OH D3), and 24,25-dihydroxyvitamin D3 (24,25-[OH]2D3) in the management of chronic renal insufficiency are reviewed. Patients with mild to moderate osteitis fibrosa experience substantial improvement with either calcitriol or 1 alpha-OH D3 therapy. However, few patients experience a reversal to normal in histologic characteristics of bone. The conditions of patients with osteomalacia do not respond to either calcitriol or 1 alpha-OH D3 therapy. The bone lesion appearing in these patients is most likely a toxic effect of aluminum. The prognosis is usually poor, but the conditions of some patients may respond to administration of 24,25-(OH)2D3 together with calcitriol. Preliminary data suggest that use of chelating agents may be beneficial. In this group of patients, 24,25-(OH)2D3 administration together with calcitriol may be beneficial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|